Homocysteine, MTHFR and methylation: what is real and what is overhyped
Homocysteine is an amino acid your body makes and then clears using folate, B12 and B6. When that clearance falters, the level rises, which is why a high reading often just means a B-vitamin shortfall or reduced kidney function. The MTHFR C677T gene variant is genuinely common and nudges homocysteine up a little, but its independent effect on heart disease is tiny, and large trials that lowered homocysteine with B vitamins did not cut heart attacks or strokes. The honest summary: homocysteine is a useful flag, methylation is real biochemistry, and most of the commercial “methylation” hype runs far ahead of the evidence.
Key facts
- Homocysteine sits in the middle of the methylation cycle: it is either recycled back to methionine (needing folate and B12) or broken down (needing B6). A shortfall in any of these three raises it.1
- The MTHFR C677T “TT” genotype reduces enzyme activity by around 70 percent and raises homocysteine by roughly 20 percent, but a large meta-analysis found only about a 2 percent higher coronary risk in TT versus CC.2
- A meta-analysis of 8 randomised trials in 37,485 people found that lowering homocysteine with folic acid and B vitamins did not reduce heart attacks, strokes (within the trials), cancer or death.3
- Head-to-head, folic acid and methylfolate lower homocysteine by similar amounts; methylfolate raises red-cell folate as well or better and avoids unmetabolised folic acid.7
What homocysteine is and why it matters
Homocysteine is a sulphur-containing amino acid generated as a by-product when cells use methionine to donate methyl groups, the process loosely called methylation that switches genes on and off and maintains myelin. The body clears it two ways: remethylation back to methionine, needing folate (via the MTHFR enzyme) and B12, and transsulphuration down a disposal route, needing B6.1 A raised level is therefore rarely a disease in itself. It is a signal that one of those routes is blocked, which is why homocysteine is best read as a clue, not a target. It sits close to the B-vitamin picture in our guide to B12 and folate deficiency.
The B-vitamin connection: folate, B12 and B6
Because the three vitamins sit at different points on the cycle, the result can hint at the cause. Folate and B12 both feed remethylation, so a shortfall in either pushes homocysteine up; usefully, B12 deficiency also raises methylmalonic acid (MMA), whereas folate deficiency leaves MMA normal.1 B6 sits on the disposal arm. In practice the commonest reasons a UK adult shows a mildly raised value are unremarkable: low dietary folate, low or borderline B12 (older people, vegans, long-term metformin or acid-suppressing drugs), reduced kidney function, or simply a fast before the blood draw. Most of that is correctable with food or a sensible dose of the right B vitamin.
Order of operations: never correct folate before B12 has been checked. Folic acid can tidy up the blood count of a B12 deficiency while the neurological damage continues unseen. Test folate and B12 together, and address B12 first or alongside.8
The MTHFR C677T variant: common, usually minor
MTHFR is the gene for the enzyme that makes the active folate used in remethylation. The much-discussed C677T variant (rs1801133) yields a slightly less stable enzyme. Two copies (the “TT” genotype) lose roughly 70 percent of activity in the laboratory; one copy loses around 40 percent.2 It is genuinely common, with roughly 8 to 15 percent of many European populations being TT. But the real-world effect is small: when folate intake is adequate, TT individuals run homocysteine about 20 percent higher than CC, and that gap shrinks as folate rises. Crucially, a meta-analysis using the variant as a natural experiment and avoiding publication bias found the excess coronary heart disease risk in TT versus CC was only about 2 percent.2 For most carriers, C677T is a footnote, not a diagnosis.
Evidence note: C677T is a well-replicated common variant (strong genetic data). What is overstated is its clinical weight. It raises homocysteine modestly and adds little independent cardiovascular risk in folate-replete populations, and there is no good evidence that routine MTHFR genotyping improves outcomes in an otherwise healthy person.
The folic acid versus methylfolate debate
The commercial argument runs: because C677T carriers convert folic acid less efficiently, they must take the pre-converted active form, methylfolate (5-MTHF). The biochemistry is real, but the leap to “everyone with MTHFR should avoid folic acid” is not. In head-to-head trials, folic acid and methylfolate lower homocysteine by comparable amounts; methylfolate raises red-cell folate as well or better, avoids the build-up of unmetabolised folic acid at high doses, and does not mask B12 deficiency the way folic acid can.78 So methylfolate is a reasonable, slightly pricier choice, especially at higher doses or for known TT carriers. But neural-tube-defect prevention and UK policy rest on folic acid, including the new mandatory fortification of non-wholemeal wheat flour at 250 micrograms per 100 grams, legislated in England in November 2024.6 The data do not show ordinary folic acid failing C677T carriers at sensible doses.
| Feature | Folic acid | Methylfolate (5-MTHF) |
|---|---|---|
| Lowers homocysteine | Yes | Yes, by a similar amount7 |
| Needs MTHFR conversion | Yes (less efficient in TT) | No (already active) |
| Raises red-cell folate | Yes | Equal or better7 |
| Unmetabolised folic acid at high dose | Possible | Avoided |
| Can mask B12 deficiency anaemia | Yes | Less so8 |
| Evidence base for neural tube defect prevention | Large and established | Limited |
When a high homocysteine is worth acting on
Take it seriously when it is clearly elevated and there is a plausible, fixable cause. Most laboratories treat roughly 15 micromol/L as the upper end of normal, under 10 to 12 as comfortable, with higher values at older ages and reduced kidney function. A meaningfully raised result should prompt a check of the obvious drivers: folate, B12 (with MMA if borderline), B6, kidney function and thyroid.1 Very high levels (for example above 30 to 50 micromol/L) point to B12 deficiency or, rarely, an inherited metabolic disorder needing specialist input. The harder question is whether lowering it changes long-term health, and here the evidence is sobering.
The disappointing heart and stroke trials
Observational and genetic data once suggested homocysteine was causal: a 2002 BMJ meta-analysis estimated that lowering it by 3 micromol/L might cut ischaemic heart disease by around 16 percent and stroke by around 24 percent.4 That launched a generation of trials, which largely failed it. A pooled analysis of 8 randomised trials in 37,485 people found B-vitamin supplementation lowered homocysteine but produced no significant reduction in coronary events, stroke, cancer or death.3 A 2017 Cochrane review agreed: no evidence that lowering homocysteine with B6, B9 or B12 prevents cardiovascular events, with its trial sequential analysis concluding no further trials were needed.5 Some meta-analyses suggest a modest stroke reduction, plausibly larger in folate-poor populations without fortification, but the headline holds: taking B vitamins purely to push a number down is not a proven way to protect the heart.
Be wary of clinics that genotype MTHFR, find a common variant, then sell open-ended high-dose methylated B-complexes, methylfolate megadoses or injections to “optimise methylation.” The trial evidence does not support homocysteine-lowering for cardiovascular prevention in the general population, and very high B6 over long periods can cause peripheral nerve damage (sensory neuropathy). This is general information, not a recommendation to start or stop any supplement.
The one area with more promise: the ageing brain
The most credible signal is cognitive. The UK VITACOG trial gave high-dose folic acid, B12 and B6 to older adults with mild cognitive impairment. Over two years it slowed brain shrinkage on MRI, with later analysis finding cognitive benefit, but the effect was concentrated in those who started with homocysteine above the median.9 This is promising rather than proven: a single-centre trial in a selected group, with larger prevention trials mixed, and it does not justify population-wide use. When weighing up several supplements, our stack builder helps separate what is evidence-led from what is not, and our insights articles explain how to read this kind of subgroup result.
A grounded take that cuts through the hype
Methylation is real, important biochemistry. “Methylation support” as sold online is mostly marketing built on three moves: treating a common, low-impact gene variant as a diagnosis, implying folic acid is dangerous when fortification has prevented thousands of neural tube defects, and quietly skipping the trials that found no cardiovascular benefit. The sensible position is unglamorous: eat folate-rich food, keep B12 adequate (especially if older, vegan or on metformin or acid suppressants), check homocysteine only when there is a reason, and fix the cause if it is high. New readers can orient with our start page.
What to ask your GP
- My homocysteine is raised: can we check folate, B12 (with MMA if borderline), kidney function and thyroid to find the cause?
- Can we confirm B12 status before I take any folic acid or methylfolate, so we do not mask a B12 problem?
- I have an MTHFR C677T variant: does it change my management, or is my folate and B12 status what matters?
- Is there evidence that lowering my homocysteine with B vitamins would reduce my heart or stroke risk?
References
- Selhub J. Homocysteine metabolism. Annual Review of Nutrition. 1999;19:217-246. PMID 10448523.
- Clarke R, Bennett DA, Parish S, et al. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLOS Medicine. 2012;9(2):e1001177. journals.plos.org.
- Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37,485 individuals. Archives of Internal Medicine. 2010;170(18):1622-1631. jamanetwork.com.
- Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325(7374):1202. PMC135491.
- Marti-Carvajal AJ, Sola I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews. 2017;(8):CD006612. cochranelibrary.com.
- Department of Health and Social Care. Folic acid added to flour to prevent spinal conditions in babies; The Bread and Flour (Amendment) (England) Regulations 2024. GOV.UK, 2024. gov.uk.
- Venn BJ, Green TJ, Moser R, Mann JI. Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine. American Journal of Clinical Nutrition. 2003;77(3):658-662. PMID 12600857.
- National Institute for Health and Care Excellence. Vitamin B12 deficiency in over 16s: diagnosis and management. NICE guideline NG239, 2024. nice.org.uk.
- Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLOS One. 2010;5(9):e12244. journals.plos.org.
This article is educational and does not constitute medical advice, diagnosis, or a treatment recommendation. Medication uses described as “off-label” are not licensed for that purpose in the UK and should only be considered under qualified clinical supervision. Always speak to your GP, pharmacist, or a registered specialist before starting, stopping, or changing any treatment. If you have severe or alarm symptoms - unintentional weight loss, blood in your stool, difficulty swallowing, persistent vomiting, a fever, or severe pain - seek urgent medical care.